leukemia

[Neurotherapeutics] Individuals with HIV-associated amyotrophic lateral sclerosis (ALS) show a remarkable response to antiretroviral therapy; however, antiretroviral trials in ALS down-regulate HML-2 without ameliorating the disease.

[SELLAS Life Sciences Group, Inc.] SELLAS Life Sciences Group, Inc. announced that the first acute myeloid leukemia patient has enrolled in the fifth dose level cohort, out of the expected six dose cohorts, in the ongoing Phase I dose-escalating clinical trial with SELLAS’ newly in-licensed GFH009 asset.

[Acta Biomaterialia] Researchers compared the anti-leukemic ability of pure ABT-199 and PEG-ABT-199 in vitro and in vivo.

[Cell Death & Disease] Scientists discovered that hematopoietic stem and progenitor cells were mainly targeted by acute lymphoblastic leukemia extracellular vesicles, affecting their quiescence and maintenance in the murine bone marrow environment.

[Cell Death Discovery] Researchers showed that hydroxyurea could kill mixed-lineage leukemia-r acute myeloid leukemia cells through the necroptosis process.

[Nature Communications] Utilizing single-cell RNA and T cell receptor profiling, researchers showed that irrespective of STAT3 mutation status, T cell large granular lymphocytic leukemia clonotypes were more cytotoxic and exhausted than healthy reactive clonotypes.